Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT04930562 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

GVHD, Chronic

Interventions

DRUG: BN101

Sponsor

BioNova Pharmaceuticals (Shanghai) LTD.